Sepsis-specific treatment market set to grow to $354 million in 2021; report

Following the first sepsis-specific product launch in 2016, the treatment market will expand at a compound annual growth rate (CAGR) of 69% to reach $354 million by 2021 across the six major markets (6MM) of the USA, UK, France, Germany, Italy and Spain.

According to research and consulting firm GlobalData’s latest report, this growth will be driven by the increased uptake of novel therapies, led by Asahi Kasei Pharma America’s (AKP-A’s) anti-coagulant ART-123 (recombinant human soluble thrombomodulin alpha), as the critical care community regains confidence in sepsis-specific products and more data is generated on their overall efficacy and safety.

GlobalData projects that the sepsis-specific treatment space will be valued at $25.7 million across the 6MM in 2016, supported by the expected regulatory approval of ART-123, with the USA accounting for almost 80% of sales, or $20.3 million.